公开(公告)号：US20100261677A1

公开(公告)日：2010-10-14

申请号：US12676319

申请日：2008-09-04

Applicant: Elke Langkopf ,  Alexander Pautsch ,  Corinna Schoelch ,  Annette Schuler-Metz ,  Ruediger Streicher ,  Holger Wagner

Inventor： Elke Langkopf ,  Alexander Pautsch ,  Corinna Schoelch ,  Annette Schuler-Metz ,  Ruediger Streicher ,  Holger Wagner

IPC: A61K31/675 ,  C07F9/28 ,  A61K31/662 ,  A61P3/10

CPC classification number: C07D215/38 ,  C07D217/22 ,  C07D219/08 ,  C07D231/56 ,  C07D237/28 ,  C07D239/42 ,  C07D239/72 ,  C07D239/74 ,  C07D241/42 ,  C07D263/56 ,  C07D277/66 ,  C07D471/04

Abstract: The invention relates to substituted arylsulphonylaminomethylphosphonic acid derivatives of general formula (I) wherein the groups Ra to Rf, A and Z are defined as mentioned in the specification and claims, which are suitable for preparing a medicament for the treatment of metabolic disorders, particularly type 1 or type 2 diabetes mellitus.

Abstract translation: 本发明涉及通式（I）的取代芳基磺酰基氨基甲基膦酸衍生物，其中基团Ra至Rf，A和Z定义如说明书和权利要求中所述，其适用于制备用于治疗代谢紊乱的药物，特别是类型 1或2型糖尿病。

公开(公告)号：US07709480B2

公开(公告)日：2010-05-04

申请号：US11313380

申请日：2005-12-21

Applicant: Georg Dahmann ,  Frank Himmelsbach ,  Bernd Krist ,  Martin Lenter ,  Alexander Pautsch ,  Gisela Schapp ,  Martin Steegmaier ,  Helmut Wittneben ,  Anthony S. Prokopowicz ,  Walter Spevak ,  Andreas Schoop ,  Steffen Steurer

Inventor： Georg Dahmann ,  Frank Himmelsbach ,  Bernd Krist ,  Martin Lenter ,  Alexander Pautsch ,  Gisela Schapp ,  Martin Steegmaier ,  Helmut Wittneben ,  Anthony S. Prokopowicz ,  Walter Spevak ,  Andreas Schoop ,  Steffen Steurer

IPC: C07D417/00 ,  C07D239/48 ,  A61K31/506

CPC classification number: C07D239/48 ,  C07D231/12 ,  C07D233/56 ,  C07D239/50 ,  C07D239/80 ,  C07D249/08 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D451/04 ,  C07D451/06 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10

Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterized by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.

Abstract translation: 本发明涉及式（I）的三取代嘧啶，其中0Ra至Re如权利要求1所定义，其适用于治疗以细胞增殖过度或异常为特征的疾病，其用于制备具有上述药物组合物的用途 性质及其制备方法。

公开(公告)号：US20070259855A1

公开(公告)日：2007-11-08

申请号：US11690360

申请日：2007-03-23

Applicant: Udo Maier ,  Matthias Grauert ,  Matthias Hoffmann ,  Christoph Hoenke ,  Anne Joergensen ,  Alexander Pautsch ,  Trixi Brandl ,  Steffen Breitfelder ,  Stefan Scheuerer ,  Klaus Erb ,  Michael Pieper ,  Ingo Pragst

Inventor： Udo Maier ,  Matthias Grauert ,  Matthias Hoffmann ,  Christoph Hoenke ,  Anne Joergensen ,  Alexander Pautsch ,  Trixi Brandl ,  Steffen Breitfelder ,  Stefan Scheuerer ,  Klaus Erb ,  Michael Pieper ,  Ingo Pragst

IPC: A61K31/429 ,  A61K31/428 ,  A61K31/44 ,  A61K31/517 ,  A61K31/549 ,  A61K31/55 ,  A61K31/551 ,  A61P11/00 ,  A61P17/00 ,  A61P19/00 ,  A61P29/00 ,  A61P31/00 ,  A61P37/00 ,  C07D417/06 ,  C07D513/04

CPC classification number: C07D513/04

Abstract: Disclosed are compounds of general formula (I), wherein the groups R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-indazoles and the use thereof as pharmaceutical compositions.

Abstract translation: 公开了通式（I）的化合物，其中基团R 1，R 2，R a和R b， SUP>具有权利要求书和说明书中给出的含义，互变异构体，外消旋体，对映异构体，非对映体及其混合物，以及任选的药理学上可接受的酸加成盐，溶剂合物和水合物，以及制备这些噻唑基 - 二氢 - 吲唑的方法和 其作为药物组合物的用途。

公开(公告)号：US20060106013A1

公开(公告)日：2006-05-18

申请号：US11244299

申请日：2005-10-05

Applicant: Steffen Breitfelder ,  Udo Maier ,  Trixi Brandl ,  Christoph Hoenke ,  Matthias Grauert ,  Alexander Pautsch ,  Matthias Hoffmann ,  Frank Kalkbrenner ,  Anne Joergensen ,  Gerhard Schaenzle ,  Stefan Peters ,  Frank Buettner ,  Eckhart Bauer

Inventor： Steffen Breitfelder ,  Udo Maier ,  Trixi Brandl ,  Christoph Hoenke ,  Matthias Grauert ,  Alexander Pautsch ,  Matthias Hoffmann ,  Frank Kalkbrenner ,  Anne Joergensen ,  Gerhard Schaenzle ,  Stefan Peters ,  Frank Buettner ,  Eckhart Bauer

IPC: A61K31/5377 ,  A61K31/496 ,  A61K31/454 ,  A61K31/43 ,  C07D498/02

CPC classification number: C07D513/04 ,  C07D277/84

Abstract: New compounds of formula 1 are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory diseases of the gastrointestinal tract and motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic conditions involving autoimmune reactions or inflammations of the kidney.

Abstract translation: 提供新的式1化合物，其由于其药物活性，因为PI3-激酶调节剂可用于治疗炎症或过敏性疾病的治疗领域。 这些实例包括炎性和过敏性呼吸道疾病，胃肠道炎症性疾病和运动器官，炎性和过敏性皮肤疾病，炎症性眼病，鼻粘膜疾病，涉及自身免疫反应或炎症的炎性或过敏性疾病。

公开(公告)号：US20060100211A1

公开(公告)日：2006-05-11

申请号：US11313380

申请日：2005-12-21

Applicant: Georg Dahmann ,  Frank Himmelsbach ,  Bernd Krist ,  Martin Lenter ,  Alexander Pautsch ,  Gisela Schnapp ,  Martin Steegmaier ,  Helmut Wittneben ,  Anthony Prokopowicz ,  Walter Spevak ,  Andreas Schoop ,  Steffen Steurer

Inventor： Georg Dahmann ,  Frank Himmelsbach ,  Bernd Krist ,  Martin Lenter ,  Alexander Pautsch ,  Gisela Schnapp ,  Martin Steegmaier ,  Helmut Wittneben ,  Anthony Prokopowicz ,  Walter Spevak ,  Andreas Schoop ,  Steffen Steurer

IPC: C07D403/02 ,  A61K31/501 ,  A61K31/506

CPC classification number: C07D239/48 ,  C07D231/12 ,  C07D233/56 ,  C07D239/50 ,  C07D239/80 ,  C07D249/08 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D451/04 ,  C07D451/06 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10

Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.

Abstract translation: 本发明涉及如权利要求1所定义的式（I）的三取代嘧啶，其中R 1和R 2定义如权利要求1所述，其适用于治疗以过量为特征的疾病 或异常细胞增殖，其用于制备具有上述性质的药物组合物的用途及其制备方法。